Sab Biotherapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Sab Biotherapeutics Inc in the second quarter 2026?
Sab Biotherapeutics Inc recorded a cumulative net loss of $-13 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -6.74%.

Within the Biotechnology & Pharmaceuticals industry 21 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2034 to 2347.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	1687.46 %	961.54 %	483.35 %	347.32 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-13	0	13	19	-37
Return On Equity (TTM)	-6.74 %	-0.29 %	15.17 %	33.39 %	-153.92 %
SABS's Total Ranking	# 2347	# 2034	# 686	# 220	# 2882
Equity (TTM) in Millions	215	227	151	165	12
Seq. Equity Change	-5.48 %	50 %	-8.23 %	1273.76 %	-43.87 %
Seq. Net Income Change	-	-	-	-	-

Back to SABS Management Effectiveness >> SABS's 5 Years Annual ROE >> Compare SABS ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 22
Sector	# 224
Overall	# 2347

Return On Equity Statistics
High	Average	Low
33.39 %	-63.92 %	-153.92 %
(Sep 30 2025)		(Jun 30 2025)

SABS Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	151	26	57	31	39
Y / Y Equity Change	483.35 %	-54.68 %	84.49 %	-19.43 %	-1.17 %
Net Income in Millions	13	-34	-42	-19	-17
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	8.76 %	-131.33 %	-73.64 %	-60.34 %	-44.47 %

Back to SABS Management Effectiveness >> SABS's 5 Years Annual ROE >> Compare SABS ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 8.76 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SABS's' Return on Equity at Yahoo Finance
SABS's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SABS's Competitors
Subscribers only: Roe for Sab Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Equity for SABS's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:39:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.